POZ Platform™
Our proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be dosed via IV, SC or IM routes to address a broad range of clinical indications.
Small Molecule Conjugates
We have a pipeline of wholly-owned CNS drug candidates, addressing large markets with significant unmet need.
RNA Vaccines & Therapeutics
Our collaborations with partners to advance LNP based drug delivery in mRNA immunology highlights the broad potential of our POZ platform technology.
Antibody-Drugs (ADCs)
POZ enables optimized targeting of cancer killing cytotoxins to potentially improve treatment efficacy.
Join Us.
We’re pioneering bold new science.